Recombinant SPAG9 protein will be used for Phase II Human clinical trials using dendritic cell based vaccine in cervical cancer patients at Cancer Institute, Adiyar, Chennai.

Approval granted from Directorate General of Health Services Office of Drugs Controller General (India) Biological Division: F. No: Stm-CI/44/WIA/14-BD (DCGI) Protocol No. CI/MOL ONC/DC VACCINE, Version 5.0 [DCG (I)] for Human clinical trials.

Recombinant SPAG9 manufacturing has been outsourced to Syngene International (Biocon Limited), Bangalore, for Human clinical trials.

Approval has been obtained from Review Committee on Genetic Manipulation [RCGM], Department of Biotechnology for handing over the recombinant human SPAG9 for clinical trials.

All approvals have been obtained including Institutional Biosafety committee [IBSC], Institute Human Ethics committee [IHEC], NII

Human Clinical trials are expected to start during March 2016

If successful, this will be an important advance and an example of translational research outcome from persistent work of high quality.
Publications


Patents


